{"entity":{"id":"paper-olympiad-nejm-2017","kind":"paper","name":"OlympiAD: olaparib versus chemotherapy in metastatic breast cancer with a germline BRCA mutation","aka":[],"tldr":"In women with metastatic HER2-negative breast cancer and an inherited BRCA mutation, the PARP inhibitor tablet olaparib delayed progression by almost three months compared with chemotherapy and caused fewer severe side effects.","summary":"Phase 3 trial of 302 patients with HER2-negative metastatic breast cancer and a germline BRCA1 or BRCA2 mutation, previously treated with up to two chemotherapy lines, randomised 2:1 to olaparib or single-agent chemotherapy of physician's choice.\n\nMedian progression-free survival was 7.0 versus 4.2 months (hazard ratio 0.58) with a response rate of 59.9 versus 28.8 percent; overall survival was not significantly different, though a benefit appeared in patients who had not received chemotherapy for metastatic disease.","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2017","url":"https://doi.org/10.1056/NEJMoa1706450"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/28578601/"}],"tags":[],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":[],"targets":[],"drugs":["olaparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["olympiad"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2017,"doi":"10.1056/NEJMoa1706450","pmid":"28578601","authors":"Robson M, Im SA, Senkus E, et al.","paperType":"rct","findings":["Median progression-free survival 7.0 vs 4.2 months; hazard ratio 0.58.","Objective response 59.9 percent vs 28.8 percent; grade 3 or worse adverse events 36.6 percent vs 50.5 percent."],"whatItMeans":"Germline BRCA testing became part of metastatic breast cancer work-up, and olaparib (with talazoparib after EMBRACA) is a standard option, especially for triple-negative disease.","caveats":["No overall survival benefit in the whole population.","Platinum chemotherapy was not in the comparator arm."],"changedPractice":true,"participants":302},"route":"/key-papers/paper-olympiad-nejm-2017/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"trial":[{"id":"olympiad","kind":"trial","name":"OlympiAD","route":"/trials/olympiad/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}